Regular Article
Evidence for Autocrine Actions of Neuromedin B and Gastrin-releasing Peptide in Non-small Cell Lung Cancer

https://doi.org/10.1006/pupt.1999.0210Get rights and content

Abstract

Gastrin-releasing peptide (GRP), a member of the bombesin family of peptides, has been shown to have mitogenic activity in small cell lung carcinoma (SCLC), and to be produced by SCLC in an autocrine fashion. In this report, we demonstrate that both GRP and another member of the bombesin family of peptides, neuromedin B (NMB), are also autocrine growth factors for non-small cell lung carcinoma (NSCLC). Using the reverse transcription-polymerase chain reaction (RT-PCR), we have detected mRNA for the neuromedin B receptor (NMBR) in all 14 of the NSCLC cell lines examined. GRP receptor (GRPR) mRNA was also expressed in the majority of NSCLC cell lines (nine of 14). By immunoblotting using SDS–PAGE gradient gels fixed in trichloroacetic acid, GRP and NMB were found in fractions of culture medium that had been purified by high pressure liquid chromatography (HPLC) from NSCLC cell lines. NMB was detected in the conditioned medium of seven of nine cell lines and GRP in seven of nine cell lines; both peptides were produced in six cell lines. In four of the cell lines where both peptides were produced, the relative amount of NMB secreted into the medium was 7–15 times that of GRP; in the other two cases, the relative amounts of GRP and NMB were equivalent. Cultured human bronchial epithelial (HBE) cells expressed the GRPR and NMBR but did not produce either peptide. A subline of A549 cells that was adapted to grow in serum-free and growth factor-free conditions, termed A549-R0, secreted both bombesin-like peptides (BLPs) into the culture medium. Using either a colony-forming assay or a BrDU incorporation assay, both NMB and GRP were found to be mitogens for three NSCLC cell lines that express mRNA for BLP receptors and secrete BLPs, regardless of which peptide and/or receptor subtype was detected. The monoclonal antibody 2A11, which preferentially recognizes GRP, was able to block the in vitro proliferative response to GRP in the BrDU incorporation assay, and partially blocked the response to NMB. The 2A11 antibody could only partially block the in vivo growth of cell lines that showed proliferative responses to BLPs. 2A11 antibody was more effective against the 239T cell line, which secreted a low amount of GRP into the medium (0.6 nM), compared to the 201T cell line, which secreted a higher amount of both GRP and NMB (4.2 nM and 36.6 nM, respectively). These results suggest that both NMB and GRP are autocrine growth factors for NSCLC, but that the production of NMB and expression of the NMBR may be more prominent than the production of GRP and expression of the GRP receptor. If BLP ligand-receptor systems are to be targeted therapeutically in NSCLC, it will be necessary to inhibit both NMB and GRP.

References (36)

  • JM Eden et al.

    PD 165929 – The first high affinity non-peptide neuromedin-B (NMB) receptor selective antagonist

    Bioorgan Med Chem Lett

    (1996)
  • V Ashwood et al.

    PD 176252 – The first high affinity non-peptide gastrin-releasing peptide (BB2) receptor antagonist

    Bioorgan Med Chem Lett

    (1998)
  • RF Hoyt et al.

    Dynamics of neuroepithelial body (NEB) formation in developing hamster lung: light microscopic autoradiography after3H-thymidine labeling in vivo

    Anat Rec

    (1990)
  • D Adriaensen et al.

    Neuroendocrine cells and nerves of the lung

    Anat Rec

    (1993)
  • RF Hoyt et al.

    Neuroepithelial bodies and growth of the airway epithelium in developing hamster lung

    Anat Rec

    (1993)
  • ME Sunday et al.

    Bombesin increases fetal lung growth and maturation in utero and in organ culture

    Am J Respir Cell Molec Biol

    (1990)
  • DN Carney et al.

    Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide

    Cancer Res

    (1987)
  • F Cuttitta et al.

    Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer

    Nature

    (1985)
  • Cited by (86)

    • GPCRs in head and neck squamous cell carcinoma

      2019, Improving the Therapeutic Ratio in Head and Neck Cancer
    • A possible new target in lung-cancer cells: The orphan receptor, bombesin receptor subtype-3

      2018, Peptides
      Citation Excerpt :

      Our results differ from previous studies examining BRS-3 expression in lung-cancer cells, which report its presence in only 29% of 56 lung-cancer cell-lines (n = 6 studies) [10,13,14,55,61,64], whereas we found it in 62% by this PCR method. Our results are similar to previous studies with NMBR/GRPR expression in different subtypes of lung-cancer, which reported NMBR in 77% of 57 lung-cancer cells (n = 7 studies) [8,10,14,55,61,64,73] and GRPR in 66% of 61 different lung-cancer cell-lines examined (n = 7 studies) [8,10,14,55,61,64,73]. These results demonstrate that BRS-3, in contrast to previous studies, is as frequent in lung-cancer cells as the other BnRs, GRPR/NMBR and it is frequently present at high levels.

    View all citing articles on Scopus
    f1

    Author for correspondence at: Department of Pharmacology, 13th Floor, Biomedical Science Tower, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA. Fax: 412 648 2229.

    View full text